Overview

3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Drugs used in chemotherapy, such as cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. 3-AP may help cytarabine kill more cancer cells by making them more sensitive to the drug. This phase I trial is studying the side effects and best dose of 3-AP when given with high-dose cytarabine in treating patients with advanced hematologic malignancies
Phase:
Phase 1
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Cytarabine